Clinical Trial Update: Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing fesoterodine for amelioration of autonomic dysreflexia after spinal cord injury has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Dysreflexia

Drugs mentioned

• Fesoterodine (fesoterodine)

Snippet

Sponsor: University of British Columbia | Conditions: Autonomic Dysreflexia | Phase 2 | Status: COMPLETED